Galera Therapeutics (GRTX)
OTHER OTC:GRTX
Want to see GRTX full AI Analyst Report?
GRTX Stock Chart & Stats
$0.02
<$0.01(0.99%)
At close: 4:00 PM EST
$0.02
<$0.01(0.99%)
Day’s Range― - ―
52-Week Range$0.02 - $0.15
Previous CloseN/A
Volume48.38K
Average Volume (3M)63.57K
Market Cap
$16.07M
Enterprise Value$2.10M
Total Cash (Recent Filing)$6.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.82
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding160,429,780
10 Day Avg. Volume87,114
30 Day Avg. Volume63,573
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.36
Enterprise Value/Market Cap0.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.35
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Merger And $350M FinancingThe definitive Obsidian merger plus an oversubscribed $350M private placement materially extends funding visibility into 2H 2028 and repositions Galera into a larger immuno-oncology platform. This provides durable operational runway to execute clinical milestones and de-risks near-term capital needs.
Balance-sheet DeleveragingA shift from heavy leverage in 2024 to zero reported debt and positive equity in 2025 meaningfully lowers financial risk and interest burden. The repair improves capital structure flexibility and credibility with counterparties, supporting longer-term strategic options despite a still-modest asset base.
Simplified Equity StructureEliminating the Series B preferred class simplifies governance, improves transparency, and aligns holders under a single common share class. This structural simplification reduces complexity for future financings or transactions and strengthens corporate governance clarity over the medium term.
Bears Say
Pre-revenue Operating LossesGalera has been a pre-revenue biotech with zero product sales and persistent negative operating results, driving material cash burn historically. Without durable positive operating cash flow or commercialization, the company remains dependent on external financing and partner/transaction outcomes for survival.
Thin Capital CushionEven after deleveraging, the balance sheet shows modest assets (~$7.2M) and a thin equity cushion (~$4.0M). That limited capital base constrains flexibility against clinical setbacks, increases vulnerability to unexpected expenses, and means future operating disruptions could require rapid additional financing.
Material Dilution And Minority Stake RiskThe merger structure and concurrent financing leave legacy Galera holders with a pro forma minority (~1.8%) and the charter increase plus outstanding pre-funded warrants create clear dilution capacity. This structurally reduces existing shareholders' economic upside and governance influence over the combined company's trajectory.
Galera Therapeutics News
GRTX FAQ
What was Galera Therapeutics’s price range in the past 12 months?
Galera Therapeutics lowest stock price was $0.01 and its highest was $0.15 in the past 12 months.
What is Galera Therapeutics’s market cap?
Galera Therapeutics’s market cap is $16.07M.
When is Galera Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Galera Therapeutics’s earnings last quarter?
Currently, no data Available
Is Galera Therapeutics overvalued?
According to Wall Street analysts Galera Therapeutics’s price is currently Overvalued.
Does Galera Therapeutics pay dividends?
Galera Therapeutics does not currently pay dividends.
What is Galera Therapeutics’s EPS estimate?
Galera Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galera Therapeutics have?
Galera Therapeutics has 160,429,780 shares outstanding.
What happened to Galera Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Galera Therapeutics?
Currently, no hedge funds are holding shares in GRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galera Therapeutics
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Technical Analysis
Ownership Overview
8.95% Insiders
<0.01% Mutual Funds
1.83% Other Institutional Investors
89.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---